Back to results
Bibliographic record · Consultation and access
Artículo

Murine models of dengue virus infection for novel drug discovery

Byrne, Alana Brooke et al · Informa Healthcare · 2022

Supplementary material available
Quick overview. Review the resource’s basic details, then access the content using the main button. This page shows only the information needed to identify, cite, and open the work.

Resource access

Open the content from the main option or choose another available source.

CONICET Digital CONICET Digital OAI-PMH
Entrar por CONICET Digital
Main access

Supplementary material available

El enlace apunta a material asociado, anexos, tablas, datos o página complementaria. No se marca como libro/texto completo.
Open material

Summary

Descripción general del contenido del recurso.

Introduction: Dengue virus (DENV) is the causative agent of the most prevalent human disease transmitted by mosquitoes in tropical and subtropical regions worldwide. At present, no antiviral drug is available and the difficulties to develop highly protective vaccines against the four DENV serotypes maintain the requirement of effective options for dengue chemotherapy. Areas covered: The availability of animal models that reproduce human disease is a very valuable tool for the preclinical evaluation of potential antivirals. Here, the main murine models of dengue infection are described, including immunocompetent wild-type mice, immunocompromised mice deficient in diverse components of the interferon (IFN) pathway and humanized mice. The main findings in antiviral testing of DENV inhibitory compounds in murine models are also presented. Expert opinion: At present, there is no murine model that fully recapitulates human disease. However, immunocompromised mice deficient in IFN-α/β and -γ receptors, with their limitations, have shown to be the most suitable system for antiviral preclinical testing. In fact, the AG129 mouse model allowed the identification of celgosivir, an inhibitor of cellular glucosidases, as a promising option for DENV therapy. However, clinical trials still were not successful, emphasizing the difficulties in the transition from preclinical testing to human treatment. Fil: Byrne, Alana Brooke. Gobierno de la Ciudad Autónoma de Buenos Aires. Hospital General de Niños "Ricardo Gutiérrez". Departamento de Medicina; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Garcia, Cybele. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Ciudad Universitaria. Instituto de Química Biológica de la Facultad de Ciencias Exactas y Naturales. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Instituto de Química Biológica de la Facultad de Ciencias Exactas y Naturales; Argentina

How to cite

Elegí el formato que necesitás y copiá la referencia al portapapeles.

APA 7

Byrne, A. B. E. A. (2022). Murine models of dengue virus infection for novel drug discovery. http://hdl.handle.net/11336/200499

MLA

Byrne, Alana Brooke et al. "Murine models of dengue virus infection for novel drug discovery." 2022. http://hdl.handle.net/11336/200499.

Chicago

Byrne, Alana Brooke et al. 2022. "Murine models of dengue virus infection for novel drug discovery.". http://hdl.handle.net/11336/200499.

Harvard

Byrne, A. B. E. A. 2022, Murine models of dengue virus infection for novel drug discovery, Informa Healthcare, available at: http://hdl.handle.net/11336/200499 [Accessed 7 Aug. 2026].

Share and print

Save the record, copy its permanent link, or print it as a PDF.

Export reference

You can export the record in common formats for use in a reference manager.

Resource details

Bibliographic information to help confirm that this is the correct material.

Title
Murine models of dengue virus infection for novel drug discovery
Author / contributors
Byrne, Alana Brooke et al
Publisher
Informa Healthcare
Publication year
2022
ISSN
1746-0441
ISSN
1746-0441
Language
English

Subjects

Explore related resources through these subjects.

Copied